Add BrightSurf on Google Email

American College of Chest Physicians


Disruption in combination inhaled corticosteroid therapy may lead to an increased rate of costly exacerbations and hospitalizations for Medicare patients

A study of 44,832 Medicare patients found that disruption in their regular combination inhaled corticosteroid therapy led to a higher rate of costly exacerbations and hospitalizations. Approximately 45% of patients did not receive an ICS/LABA after a formulary block, potentially impacting symptoms and disease control.